Last reviewed · How we verify
Ramipril and hydrochlorothiazide
Ramipril and hydrochlorothiazide is a ACE inhibitor and thiazide diuretic Small molecule drug developed by Pfizer. It is currently in Phase 3 development for Hypertension, Chronic heart failure.
Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, while hydrochlorothiazide is a thiazide diuretic that increases urine production.
Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, while hydrochlorothiazide is a thiazide diuretic that increases urine production. Used for Hypertension, Chronic heart failure.
At a glance
| Generic name | Ramipril and hydrochlorothiazide |
|---|---|
| Sponsor | Pfizer |
| Drug class | ACE inhibitor and thiazide diuretic |
| Target | ACE |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By blocking the conversion of angiotensin I to angiotensin II, ramipril reduces blood pressure and decreases the workload on the heart. Hydrochlorothiazide works by increasing the amount of urine produced by the kidneys, which helps to lower blood pressure and reduce fluid buildup in the body.
Approved indications
- Hypertension
- Chronic heart failure
Common side effects
- Cough
- Dizziness
- Headache
- Fatigue
- Muscle cramps
Key clinical trials
- Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II) (PHASE3)
- HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED) (PHASE3)
- Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting Conditions (PHASE1)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Nephropathy In Type 2 Diabetes and Cardio-renal Events (PHASE4)
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes (EARLY_PHASE1)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramipril and hydrochlorothiazide CI brief — competitive landscape report
- Ramipril and hydrochlorothiazide updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Ramipril and hydrochlorothiazide
What is Ramipril and hydrochlorothiazide?
How does Ramipril and hydrochlorothiazide work?
What is Ramipril and hydrochlorothiazide used for?
Who makes Ramipril and hydrochlorothiazide?
What drug class is Ramipril and hydrochlorothiazide in?
What development phase is Ramipril and hydrochlorothiazide in?
What are the side effects of Ramipril and hydrochlorothiazide?
What does Ramipril and hydrochlorothiazide target?
Related
- Drug class: All ACE inhibitor and thiazide diuretic drugs
- Target: All drugs targeting ACE
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Chronic heart failure
- Compare: Ramipril and hydrochlorothiazide vs similar drugs
- Pricing: Ramipril and hydrochlorothiazide cost, discount & access